• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Alcon reveals final data from Vivity Registry Study which demonstrates sustained high patient satisfaction and reduced spectacle dependence


The study monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL).

(Image Credit: AdobeStock/Livinskiy)

(Image Credit: AdobeStock/Livinskiy)

Alcon has announced final data from its Vivity Registry Study, which monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL).

Alcon stated in a press release, that data from more than 900 cataract patients demonstrated sustained clinical performance, high patient satisfaction and reduced dependence upon spectacles. Alcon also stated that evidence suggested that AcrySof IQ Vivity can be used successfully in a broad range of patients, providing surgeons and patients with additional treatment options.1

The AcrySof IQ Vivity from Alcon is a non-diffractive IOL and uses Alcon’s “proprietary Wavefront-Shaping X-WAVE technology, a next-generation optical principle that stretches and shifts light without splitting it.”

Sunil Vasanth, VP, Europe Surgical Franchise at Alcon discussed IQ Vivity in the press release from Alcon.

“Since its introduction, AcrySof IQ Vivityhas been a disruptive technology—and an innovation we are very proud of as a company. Vivityis a first-of-its kind, non-diffractive extended depth of focus IOL built with our proprietary X-WAVE technology, which stretches and shifts light without splitting it,” said Vasanth. “Our real-world registry data gives surgeons the confidence that Vivity’s performance is sustained over time. This data is also important as it includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy.”

The Vivity Registry Study was a multicentre, ambispective, non-comparative, open-label, non-interventional registry study conducted across 41 sites from 8 countries.1

Results from the Vivity Registry Study included:1

  • Three-quarters of patients reported no difficulty with their sight for activities in everyday life.
  • Most patients (92%) reported they were satisfied with their sight.
  • More than 91% of patients reported no halos, glares or starbursts(common visual disturbances that come from splitting the light in a diffractive IOL).
  • Excellent binocular distance and intermediate uncorrected visual acuity was observed, with mean Snellen visual acuity values of 20/20 and 20/25, respectively.
  • More than 78% and 88% of patients reported they no longer needed to use glasses to see at arm’s length and far away, respectively.
  1. Cataract Surgery with Alcon’s AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence. Press Release. Released September 9, 2023. Accessed September 11, 2023. https://www.alcon.com/media-release/cataract-surgery-alcons-acrysof-iq-vivity-iols-demonstrates-sustained-high-patient
Related Videos
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.